Catalytica Staffing Levels Questioned In FDA Warning Letter
Executive Summary
Catalytica expects to be re-inspected by FDA before the end of the year as a follow-up to items identified in an Oct. 29 warning letter to the contract manufacturer.
You may also be interested in...
DSM Entering U.S. Via Catalytica: European Bulk Firms Going Global
DSM plans to establish a U.S. presence for its bulk active ingredient and contract manufacturing operations through the acquisition of Catalytica Pharmaceuticals.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011